VetSRev
Database of veterinary systematic reviews
Database of veterinary systematic reviews
Int J Mol Sci (2020) 21:
DOI: 10.3390/ijms21176265
Prostate cancer is a major cause of death among men worldwide. Recent preclinical evidence implicates cannabinoids as powerful regulators of cell growth and differentiation, as well as potential anti-cancer agents. The aim of this review was to evaluate the effect of cannabinoids on in vivo prostate cancer models. The databases searched included PubMed, Embase, Scopus, and Web of Science from inception to August 2020. Articles reporting on the effect of cannabinoids on prostate cancer were deemed eligible. We identified six studies that were all found to be based on in vivo/xenograft animal models. Results: In PC3 and DU145 xenografts, WIN55,212-2 reduced cell proliferation in a dose-dependent manner. Furthermore, in LNCaP xenografts, WIN55,212-2 reduced cell proliferation by 66-69%. PM49, which is a synthetic cannabinoid quinone, was also found to result in a significant inhibition of tumor growth of up to 90% in xenograft models of LNCaP and 40% in xenograft models of PC3 cells, respectively. All studies have reported that the treatment of prostate cancers in in vivo/xenograft models with various cannabinoids decreased the size of the tumor, the outcomes of which depended on the dose and length of treatment. Within the limitation of these identified studies, cannabinoids were shown to reduce the size of prostate cancer tumors in animal models. However, further well-designed and controlled animal studies are warranted to confirm these findings.
Singh, K., Jamshidi, N., Zomer, R., Piva, T. J., & Mantri, N. (2020). Cannabinoids and Prostate Cancer: A Systematic Review of Animal Studies. Int J Mol Sci, 21(17). https://doi.org/10.3390/ijms21176265 Animals, Male, Humans, Xenograft Model Antitumor Assays, Cell Line, Tumor, cancer, Dose-Response Relationship, Drug, Cell Survival/drug effects, Cell Proliferation/drug effects, prostate cancer, animal models, systematic reviews, human diseases, antineoplastic agents, neoplasms, Non-communicable Human Diseases and Injuries [VV600], Animal and in vitro Models for Pharmaceuticals [VV450], Animal Models of Human Diseases [VV400], cancers, prostate, Tumor Burden/drug effects, inhibition, PC-3 Cells, cannabinoids, Animal Models of Human Nutrition [VV140], cytotoxic agents, cell elongation, cell growth, cannabis, Benzoxazines/pharmacology/*therapeutic use, Cannabinoids/pharmacology/*therapeutic use, Morpholines/pharmacology/*therapeutic use, Naphthalenes/pharmacology/*therapeutic use, Prostatic Neoplasms/*drug therapy/metabolism/pathology, Win55,212-2